A new study of the drug being developed by Pharmaessentia – ropeginterferon – shows that the JAK2 allele burden is reduced compared to patients on hydroxyurea. The article states “After 1 year of treatment with ropeginterferon, the ratio of JAK2-mutated to wild-type colonies grown from bone marrow progenitors was reduced by 64%, compared to 25%… Read More »ROPEGINTERFERON ALPHA-2B TARGETS JAK2V617F-POSITIVE POLYCYTHEMIA VERA CELLS IN VITRO AND IN VIVO
Dr. Gary Luker at University of Michigan has a study that he thinks people with a myeloproliferative neoplasm will be interested in. It’s a topic the MPNRF knows well as we have funded other studies who sought the same outcome, which is to create an accurate way of assessing the state of the bone marrow… Read More »STUDY AT UNIVERSITY OF MICHIGAN SEEKS TO MAKE BONE MARROW BIOPSY EASIER FOR MPN PATIENTS
Researchers used a representative sample of PV patients who were diagnosed from 2007 – 2013 from the SEER-Medicare database, to study the current recommended guidelines for the treatment of polycythemia vera patients. The SSER-Medicare database was developed by the National Cancer Institute and the Centers for Medicare and Medicaid Services and have been shown to… Read More »STUDY ASSESS CURRENT RECOMMENDED GUIDELINES FOR THE TREATMENT OF PV PATIENTS
With your support, The MPN Research Foundation has funded research that has resulted in a better understanding of Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. The publications linked below are funded by MPNRF and will be presented at the 60th Annual American Society of Hematology meeting in San Diego this December. Funding research projects like these… Read More »MPNRF FUNDED ABSTRACTS TO BE PRESENTED AT ASH 2018
The MPN Heroes Celebration Event held annually at ASH is an opportunity to recognize the individuals and organizations who work hard on behalf of the MPN community and make a difference in the lives of patients living with PV, ET, and MF. Each year at this event, the MPN Heroes Recognition Program recipients are honored… Read More »MPNRF Founder Bob Rosen honored as MPN Hero
Each year the American Society of Hematology (ASH) hosts their annual convention, where researchers, doctors, and organizations such as the MPN Research Foundation gather to discuss the ever-changing world of blood disorders and learn about the progress of research. The content below is a selection of MPN related takeaways from the convention this year, however, a more… Read More »MPN HIGHLIGHTS FROM ASH 2018
March 22, 2018 The MPN community is discussing the article by MPN researchers from MD Anderson – Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation – a retrospective study of 107 patients who discontinued ruxolitinib. The authors discussed the acquisition of additional mutations which took place in 35% of patients on Ruxolitinib, most notable the ASXL1… Read More »BLOOD ARTICLE DISCUSSES EPIGENETIC CHANGES IN MYELOFIBROSIS FOLLOWING DISCONTINUATION OF RUXOLITINIB
Cancer Research & Treatment Foundation has released the videos of presentations from their 8th International Symposium on MPNs. They host this event every other year in New York City. It is a world class event involving patient education and updates on the latest in MPN research. Videos from all presenters can be found here: http://www.crt.org/8th-International-Patient-Symposium-on-Myeloproliferative-Neoplasms-Videos The… Read More »8TH INTERNATIONAL SYMPOSIUM ON MPNS VIDEOS
Today – March 8th – is International Women’s Day. We thought we’d take this chance to highlight the work of the women working in MPN research as well as the women who are patients or caregiver to a patient. We gave our first grant to Ann Mullally in 2012 as part of the MF Challenge initiative.… Read More »INTERNATIONAL WOMEN’S DAY 2018
“Beyond Blue,” a short documentary by an awardâ€winning filmmaker, debuts to raise awareness ofMPNs MPN Heroes® 2018 nominations now open for submissionWILMINGTON, Del. – Feb. 28, 2018 – Incyte Corporation (Nasdaq:INCY) joins the National Organization for Rare Disorders (NORD), the European Organization for Rare Diseases (EURORDIS), and other rare disease health organizations and advocates in recognizing Rare… Read More »INCYTE SUPPORTS THE MYELOPROLIFERATIVE NEOPLASM COMMUNITY IN HONOR OF RARE DISEASE DAY 2018
